SCHEMBL26075292

SCHEMBL26075292

CCOc1ccc(-c2ccc(-c3cc(C)c4cc(C(F)(F)F)ccc4n3)cc2F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FEN1 P39748 4/20 0.41
▸ LMNA P02545 3/20 0.41
▸ ALOX5AP P20292 3/20 0.41
▸ TP53 P04637 2/20 0.41
▸ HMOX1 P09601 3/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ MCHR1 Q99705 2/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HTR2B P41595 2/20 0.39
▸ ACP1 P24666 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ ATM Q13315 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075411 0.94 HMOX1 (0.42) FEN1LMNAALOX5APTP53HMOX1
SCHEMBL26075973 0.92 FEN1 (0.39) FEN1LMNAALOX5APTP53MCHR1
SCHEMBL26075355 0.90 PDE2A (0.45) FEN1ALOX5APMCHR1HTR2BMAPT
SCHEMBL26075379 0.90 PTGS2 (0.44) FEN1LMNAALOX5APTP53HMOX1
SCHEMBL26075353 0.89 PDE2A (0.47) FEN1ALOX5APMCHR1HTR2BMAPT
SCHEMBL26075359 0.89 PDE2A (0.47) FEN1ALOX5APMCHR1HTR2BMAPT
SCHEMBL26075363 0.89 PDE2A (0.47) FEN1ALOX5APMCHR1HTR2BMAPT
SCHEMBL26075375 0.89 FEN1 (0.41) FEN1ALOX5APMCHR1HTR2BACP1
SCHEMBL26075335 0.89 ACP1 (0.50) FEN1LMNAALOX5APKDM4EALDH1A1
SCHEMBL26074055 0.88 LMNA (0.47) LMNATP53RAB9AMCHR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD FEN1 3899/4885LMNA 1972/4885ALOX5AP 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback